ProPhase Labs to Release Fourth Quarter Results on Tuesday, March 6th
(firmenpresse) - DOYLESTOWN, PA -- (Marketwire) -- 02/29/12 -- ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the fourth quarter and the year ended December 31, 2011, will be released before the market opens on Tuesday, March 6, 2012.
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels. For more information visit us at .
Press Only Contact:
Jenny Miranda
5W Public Relations
Tel: (212) 584-4295
Investor Relations:
Ted Karkus
Chairman of the Board, CEO
(215) 345-0919 x0
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.02.2012 - 16:30 Uhr
Sprache: Deutsch
News-ID 1088503
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DOYLESTOWN, PA
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProPhase Labs to Release Fourth Quarter Results on Tuesday, March 6th
"
steht unter der journalistisch-redaktionellen Verantwortung von
ProPhase Labs (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
